Immune Checkpoint Inhibitors Clinical Trials in Montpellier
2 recruitingMontpellier, France
Showing 1–2 of 2 trials
Recruiting
Phase 3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Cancer PatientsLiver InjurySecondary to Immune Checkpoint Inhibitors
University Hospital, Montpellier250 enrolled1 locationNCT06864481